Brind.

Barclays and UBS raised price targets for Exelixis stock, noting that AI stocks are benefiting from Trump-era tariffs.

2 reports, 2 independent Updated Oct 23

Gone quiet

Reports: 2
Developments: 2
Repetition: 0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Barclays and UBS raised price targets for Exelixis stock, noting that AI stocks are benefiting from Trump-era tariffs.

Who's involved

What this event is mainly about

Exelixis Barclays UBS

How it developed

Newest first. Tap a step to see who reported it.

Oct 23Various firms bought, sold, and adjusted stakes in Exelixis shares.1 source
- themarketsdaily.com
Jul 23Barclays and UBS raised price targets for Exelixis stock, citing AI stock benefits from Trump-era tariffs.1 source
- Insider Monkey

Keep exploring

The entities involved

Exelixis
American biotechnology company
- Exelixis and SAB Biotherapeutics are competing for investment as healthcare companies.Sat 01:26
Barclays
British bank
- Barclays dropped its target price and set an underweight rating, while Cantor Fitzgerald also issued an underweight rating for Polestar.Sun 09:36
- Barclays dropped its target price on Pilgrim’s Pride shares on November 1, 2026.Sun 08:37
UBS
Swiss multinational investment bank and financial services company
- Motilal Oswal and UBS provided stock ratings and target prices for Bank of Baroda on November 1, 2026.06:44
- UBS and Motilal Oswal maintained bullish outlooks on Dixon Technologies stock.05:45

Coverage

Newest first; wire copies grouped

Oct 23themarketsdaily.com
Jul 23Insider MonkeyExelixis Gains Analyst Confidence as Cancer Studies Advances Exelixis, Inc. (NASDAQ:EXEL) is one of the 13 Best Low Risk High Growth Stocks to Buy. The company advances its studies following a signif